KR970010743A - 프로스타글란딘 유도체 - Google Patents
프로스타글란딘 유도체 Download PDFInfo
- Publication number
- KR970010743A KR970010743A KR1019960034329A KR19960034329A KR970010743A KR 970010743 A KR970010743 A KR 970010743A KR 1019960034329 A KR1019960034329 A KR 1019960034329A KR 19960034329 A KR19960034329 A KR 19960034329A KR 970010743 A KR970010743 A KR 970010743A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- cyclodextrin inclusion
- prostaglandin
- inclusion compound
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 239000002502 liposome Substances 0.000 claims abstract 8
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 7
- 238000002360 preparation method Methods 0.000 claims abstract 5
- -1 Prostaglandin E1 ester Chemical class 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 230000017531 blood circulation Effects 0.000 claims abstract 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract 2
- 206010040943 Skin Ulcer Diseases 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 231100000019 skin ulcer Toxicity 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 241000412565 Argentina sphyraena Species 0.000 claims 1
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 claims 1
- 235000016594 Potentilla anserina Nutrition 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 하기 화학식 (1)의 프로스타글란딘 E1에스테르 유도체 또는 이의 시클로덱스트린 포접 화합물, 그들을 포함하는 리포좀 제제, 그들 제제의 제조방법 및 그들을 활성성분으로 포함하는 약학 조성물에 관한 것이다 :
상기 식에서, R1은 서로 동일한 기이며, C4-C12알킬이다.
상기 화학식 (1)의 화합물은 혈류 증가 작용을 보유하며, 말초 순환 장애, 욕창 또는 피부 궤양의 예방 및/또는 치료, 또는 혈류 유지에 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 하기 화학식 (1)의 프로스타글란딘 E1에스테르 유도체 또는 이의 시클로덱스트린 포접 화합물 :상기 식에서, R1은 서로 동일한 기이며, C4-C12알킬이다.
- 제1항에 있어서, 상기 화합물이 PGE11,3-비스(헥사노일옥시)-2-프로필 에스테르 또는 PGE11,3-비스(도데카노일옥시)-2-프로필 에스테르인 화합물.
- 제1항 또는 제2항에서 정의한 바와 같은 화학식 (1)의 프로스타글란딘 E1유도체 또는 이의 시클로덱스트린 포접 화합물 및 리포좀 막 재료를 1 :1 내지 1 : 400의 비로 함유하는 리포좀 제제.
- 제3항에 있어서, 상기 리포좀 막 재료가 디미리스토일포스파티딜콜린을 함유하는 리포좀 제제.
- 제3항에 있어서, 상기 리포좀 막 재료가 에그 레시틴을 함유하는 리포좀 제제.
- 제3항 내지 제5항 중 어느 한 항에 있어서, 동결 건조에 의해 수득할 수 있는 리포좀 제제.
- 하기 화학식 (2)의 화합물의 R3기를 제거하여 하기 화학식 (1)의 화합물을 제조하고, 필요에 따라 상기 수득한 화학식 (1)의 화합물을 이의 시클로덱스트린 포접 화합물로 전환시키는 단계를 포함하는 하기 화학식 (1)의 화합물 또는 이의 시클로덱스트린 포접 화합물의 제조방법 :상기 식에서, R1은 제1항에서 정의한 바와 동일하며; R2은 산성 조건하에서 제거될 수 있는 히드록실-보호기이다.
- 활성성분으로 제1항 또는 제2항에서 정의한 바와 같은 화학식 (1)의 프로스타글란딘 E1유도체 또는 이의 시클로덱스트린 포접 화합물과 약학적으로 허용가능한 담체를 함유하는 말초 순환 장애, 욕창 또는 피부 궤양을 예방 및/또는 치료하기 위한 약학 조성물.
- 활성성분으로 제1항 또는 제2항에서 정의한 바와 같은 화학식 (1)의 프로스타글란딘 E1유도체 또는 이의 시클로덱스트린 포접 화합물과 약학적으로 허용가능한 담체를 함유하는 혈관 복원 수술후 혈류 유지를 위한 약학 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP95-238984 | 1995-08-25 | ||
| JP23898495 | 1995-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970010743A true KR970010743A (ko) | 1997-03-27 |
| KR100227541B1 KR100227541B1 (ko) | 1999-11-01 |
Family
ID=17038205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960034329A KR100227541B1 (ko) | 1995-08-25 | 1996-08-20 | 프로스타글란딘 유도체 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5698590A (ko) |
| EP (1) | EP0760366B1 (ko) |
| KR (1) | KR100227541B1 (ko) |
| AT (1) | ATE189214T1 (ko) |
| DE (1) | DE69606364T2 (ko) |
| DK (1) | DK0760366T3 (ko) |
| ES (1) | ES2142547T3 (ko) |
| GR (1) | GR3033195T3 (ko) |
| PT (1) | PT760366E (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5131971B2 (ja) * | 2005-12-26 | 2013-01-30 | 株式会社Ｌｔｔバイオファーマ | 水溶性非ペプチド性低分子薬物含有ナノ粒子 |
| US20100104625A1 (en) * | 2007-02-16 | 2010-04-29 | Cornell University | Biodegradable compositions and materials |
| EP2156848A4 (en) * | 2007-05-14 | 2012-11-28 | Ltt Bio Pharma Co Ltd | NANOPARTICLE CONTAINING A LOW MOLECULAR WEIGHT DRUG HAVING A NEGATIVELY PROLONGED RELEASE GROUP |
| CA2724340A1 (en) * | 2008-05-14 | 2009-11-19 | Peter Thomas Roth Labs, Llc | Prostaglandin based compositions and method of use thereof |
| KR20120031954A (ko) * | 2009-05-27 | 2012-04-04 | 수캄포 아게 | 클라우딘 매개 기능을 조정하고 피부 장애를 치료하는데 사용하기 위한 프로스타글란딘 유도체를 포함하는 제약 조성물 |
| US8569279B2 (en) | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3632627A (en) * | 1968-01-05 | 1972-01-04 | Smith Kline French Lab | Glyceride derivatives of prostaglandins |
| US4054736A (en) * | 1970-06-10 | 1977-10-18 | Ono Pharmaceutical Co., Ltd. | Clathrate compounds of prostaglandins or their analogues with cyclodextrin |
-
1996
- 1996-08-20 KR KR1019960034329A patent/KR100227541B1/ko not_active IP Right Cessation
- 1996-08-22 US US08/701,486 patent/US5698590A/en not_active Expired - Fee Related
- 1996-08-23 PT PT96306174T patent/PT760366E/pt unknown
- 1996-08-23 DK DK96306174T patent/DK0760366T3/da active
- 1996-08-23 DE DE69606364T patent/DE69606364T2/de not_active Expired - Fee Related
- 1996-08-23 EP EP96306174A patent/EP0760366B1/en not_active Expired - Lifetime
- 1996-08-23 ES ES96306174T patent/ES2142547T3/es not_active Expired - Lifetime
- 1996-08-23 AT AT96306174T patent/ATE189214T1/de not_active IP Right Cessation
-
2000
- 2000-04-12 GR GR20000400889T patent/GR3033195T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE189214T1 (de) | 2000-02-15 |
| US5698590A (en) | 1997-12-16 |
| EP0760366A1 (en) | 1997-03-05 |
| GR3033195T3 (en) | 2000-08-31 |
| PT760366E (pt) | 2000-07-31 |
| KR100227541B1 (ko) | 1999-11-01 |
| EP0760366B1 (en) | 2000-01-26 |
| DK0760366T3 (da) | 2000-04-17 |
| DE69606364T2 (de) | 2000-06-08 |
| DE69606364D1 (de) | 2000-03-02 |
| ES2142547T3 (es) | 2000-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1134270A (en) | Prostaglandin vasodilators and hypotensive agents for administration topically or by injection | |
| KR890011837A (ko) | 디데하이드로 비타민 d₃유도체 | |
| DE69901951D1 (de) | Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie | |
| JPH09504543A (ja) | 白内障の予防法及び予防手段 | |
| ES2061094T3 (es) | Un procedimiento para la obtencion de una formulacion para disminuir el deseo imperioso de alcohol (craving) en el tratamiento del alcoholismo cronico. | |
| JP2005526092A (ja) | 緑内障および眼圧亢進を治療するためのプロスタグランジンＦ２α類縁体およびそれらの抗菌タンパク質との併用法 | |
| KR880000096A (ko) | 안드로겐성 원형탈모증 치료용 국소 프로스타글란딘 배합물 | |
| KR890003382A (ko) | 항 비루스성 화합물 | |
| IT1170214B (it) | Composizione farmaceutica per la cura delle arteriopatie periferiche | |
| KR960033452A (ko) | 시신경 질환의 치료를 위한 프로스타노산 화합물 | |
| KR970010742A (ko) | 프로스타글란딘 유도체 | |
| KR970010743A (ko) | 프로스타글란딘 유도체 | |
| CA2269895A1 (fr) | Utilisation d'un extrait flavonoidique de ginkgo biloba substantiellement depourvu de terpenes, dans le domaine bucco-dentaire, et composition contenant un tel extrait | |
| HUP9601751A2 (hu) | Benzotiopirán- és tienotiopiránszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| KR900012925A (ko) | 인돌 유도체 | |
| EP1227791B1 (fr) | Utilisation de composes polycycliques aromatiques en tant qu'activateurs des recepteurs de type ppars dans une composition cosmetique ou pharmaceutique | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| FR2619008A1 (fr) | Utilisation de synergistines dans des compositions pharmaceutiques ou cosmetiques anti-acneiques | |
| EP0252033B1 (en) | A "gel" pharmaceutical form containing n-(2.6-dichloro-m-tolil)-anthranilic acid (mechlophenamic acid) for use in therapy by topical application | |
| EP0020765A1 (fr) | Remede contre le glaucome | |
| FR2373528A1 (fr) | Nouveaux derives de l'acide 1-aziridino-carboxylique, procede pour leur preparation et leur application comme medicaments immuno-stimulants | |
| FR2449680A1 (fr) | Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant | |
| RU95104576A (ru) | Способ получения материала для дренажа | |
| FR2592877A1 (fr) | Derives d'ester d'acide imidazol-1-yl-carboxylique, procede pour les preparer et composition fongicide comprenant le derive comme produit actif | |
| KR900001648A (ko) | 레티노이드의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20030722 Year of fee payment: 5 |
|
| LAPS | Lapse due to unpaid annual fee |